Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
Read More
Roche is planning to initiate late-stage studies investigating potential combinations for patients with advanced skin cancer based on its immunotherapy Tecentriq, which is already on the market for lung and bladder cancer.
Read More
Cost regulators for treatments used by the NHS in England and Wales have published three sets of final guidances giving routine access to new options for lung cancer, rheumatoid arthritis and hepatitis C, and one rejecting a new therapy for melanoma.
Read More
Patients in England and Wales with a certain type of advanced skin cancer will not be getting routine access to Roche’s Cotellic/Zelboraf combination on the NHS, after it was turned down by the National Institute for Health and Care Excellence.
Read More
The National Institute for Health and Care Excellence is not backing National Health Service use of Roche’s Cotellic/Zelboraf as a treatment for melanoma.
Read More
